BriaCell (BCTX) Therapeutics announces the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study in metastatic breast cancer. “We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell’s Phase 2 study,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell’s Bria-IMT Shows Promising Survival Advantage in Metastatic Breast Cancer
- BriaCell announces updated Phase 2 survival data fro Bria-IMT
- Promising Clinical Developments and Positive Outlook Justify Buy Rating for BriaCell Therapeutics
- BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment
- BriaCell reports complete, sustained resolution of brain metastasis in patient